Loading clinical trials...

Patient-Defined Treatment Success and Preferences in Stage IV Lung Cancer Patients | Clinical Trials | Clareo Health

UNKNOWN

Patient-Defined Treatment Success and Preferences in Stage IV Lung Cancer Patients

NCT02190864•University of Nebraska

Summary

Our long-term goal is to integrate non-small cell lung cancer patient treatment preferences into clinical treatment planning.

Detailed Description

The following specific aims are proposed: Aim 1: Determine whether individual patients' preferences, characteristics, and treatment experiences affect the definition of treatment success. Aim 2: Determine how to best predict real-life patients' treatment choices based on patients' preferences of adverse events. Aim 3: Determine whether physicians are likely to change their oncologic clinical practice after receiving a detailed communication of their patients' preferences of adverse events.

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Willing and able to provide consent
•Greater than or equal to 19 years of age
•Diagnosed with stage IV non-small cell lung cancer (NSCLC)
•Able to understand spoken English
•Eligible to undergo chemotherapy for stage IV NSCLC, to include, but not limited to, those who:
•1. have not yet started chemo
•2. are currently undergoing chemo for stage IV NSCLC
•3. have completed first line stage IV NSCLC chemo or progressed to maintenance for stage IV NSCLC within the last 30 days
•4. elect to have chemo elsewhere -- not at one of the study sites
•5. decline chemo

Exclusion Criteria

•Age \<19 years
•Not willing and/or able to provide consent
•Not able to understand spoken English

Locations (8)

Moffitt Cancer Center

Tampa, Florida, United States

Kansas City VA Medical Center

Kansas City, Missouri, United States

Saint Francis Cancer Treatment Center

Grand Island, Nebraska, United States

Southeast Nebraska Cancer center

Lincoln, Nebraska, United States

Callahan Cancer Center of Great Plains Regional Medical Center

North Platte, Nebraska, United States

Nebraska-Western Iowa (NWI) VA Health Care System

Omaha, Nebraska, United States

University of Nebraska Medical Center

Omaha, Nebraska, United States

Avera Cancer Institute

Sioux Falls, South Dakota, United States

Key Dates

Start Date

December 1, 2013

Primary Completion Date

June 1, 2016

Completion Date

June 1, 2016

Last Updated

December 4, 2015

Enrollment

210

ESTIMATED participants

Conditions

Particularly Rural/Urban ResidenceGenderAgeFACT-TOI ScoresComorbid Conditions

Contacts

KM Munirul Islam, MD, PhD

CONTACT

402-559-8283 kmislam@unmc.edu

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

NCT05987241

Muscle Invasive Bladder Urothelial CarcinomaMuscle Invasive Renal Pelvis Urothelial Carcinoma+5 more

View study

RECRUITINGPHASE2

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

NCT05198830

Lung AdenocarcinomaLung Large Cell Carcinoma+2 more

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 4, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Patient-Defined Treatment Success and Preferences in Stage IV Lung Cancer Patients

Inclusion Criteria

Exclusion Criteria

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial